Disarm Therapeutics

Disarm Therapeutics is creating a new class of therapeutics to treat patients with neurological diseases by preventing axonal degeneration. Disarm is developing SARM1 inhibitors to prevent the loss of axons in patients with neurological diseases including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. Eli Lilly acquired Disarm in October 2020.

Headquarters Cambridge, MA
Pipeline Preclinical
Twitter @DisarmTx‚Äč